At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01177 SINO BIOPHARM
Not Yet Opened 11-05 16:08:23
3.580
+0.040
+1.13%
High3.610Low3.500Vol59.06M
Open3.500D1 Closing3.540Amplitude3.11%
Mkt Cap67.27BTradable Cap67.27BTotal Shares18.79B
T/O210.88MT/O Rate0.31%Tradable Shares18.79B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Greater China Stocks Rise; Shanghai Sees Largest Increase
Dow Jones  ·  11-04 15:30
Greater China Stocks Rise; Shanghai Sees Largest Increase
BRIEF-Sino Biopharmaceutical Says Acquisition Of 29.99% Equity Interest In Hob Biotech
Reuters  ·  10-31
BRIEF-Sino Biopharmaceutical Says Acquisition Of 29.99% Equity Interest In Hob Biotech
BRIEF-Sino Biopharmaceutical Posts Qtrly Profit Attributable Of RMB1.15 Bln
Reuters  ·  10-30
BRIEF-Sino Biopharmaceutical Posts Qtrly Profit Attributable Of RMB1.15 Bln
Sino Biopharmaceutical - Qtrly Profit Attributable RMB1.15 Bln
THOMSON REUTERS  ·  10-30
Sino Biopharmaceutical - Qtrly Profit Attributable RMB1.15 Bln
Sino Biopharmaceutical - Beijing Runkang Agreed to Acquire 29.99% Stake in Hob Biotech Group
THOMSON REUTERS  ·  10-30
Sino Biopharmaceutical - Beijing Runkang Agreed to Acquire 29.99% Stake in Hob Biotech Group
Sino Biopharmaceutical - Deal for RMB630.0 Million
THOMSON REUTERS  ·  10-30
Sino Biopharmaceutical - Deal for RMB630.0 Million
Sino Biopharmaceutical - Acquisition of 29.99% Equity Interest in Target Company
THOMSON REUTERS  ·  10-30
Sino Biopharmaceutical - Acquisition of 29.99% Equity Interest in Target Company
Sino Biopharmaceutical - Unit Entered Equity Transfer Agreement With Hob Biotech HK
THOMSON REUTERS  ·  10-30
Sino Biopharmaceutical - Unit Entered Equity Transfer Agreement With Hob Biotech HK
Sino Biopharmaceutical's Cancer Drug Gets Marketing Nod from NMPA After Phase III Trials
MT Newswires Live  ·  10-21
Sino Biopharmaceutical's Cancer Drug Gets Marketing Nod from NMPA After Phase III Trials
Stock Track | Sino Biopharm Shares Plunge After Major Licensing Deal
Stock Track  ·  10-08
Stock Track | Sino Biopharm Shares Plunge After Major Licensing Deal
Sino Biopharm Unit Obtains China License for YZY Bio's Cancer Drug
MT Newswires Live  ·  10-08
Sino Biopharm Unit Obtains China License for YZY Bio's Cancer Drug
BRIEF-Sino Biopharmaceutical Announces Exclusive License And Cooperation Deal With YZY Biopharma
Reuters  ·  10-08
BRIEF-Sino Biopharmaceutical Announces Exclusive License And Cooperation Deal With YZY Biopharma
Sino Biopharmaceutical - Unit Will Pay Approximately RMB315 Mln as Upfront Payment
THOMSON REUTERS  ·  10-08
Sino Biopharmaceutical - Unit Will Pay Approximately RMB315 Mln as Upfront Payment
Sino Biopharmaceutical - Unit Obtained License for Development, Commercialization of M701 Developed by Yzy Biopharma in Mainland China
THOMSON REUTERS  ·  10-08
Sino Biopharmaceutical - Unit Obtained License for Development, Commercialization of M701 Developed by Yzy Biopharma in Mainland China
Sino Biopharmaceutical - Signing of an Exclusive License and Cooperation Agreement With Yzy Biopharma
THOMSON REUTERS  ·  10-08
Sino Biopharmaceutical - Signing of an Exclusive License and Cooperation Agreement With Yzy Biopharma
Stock Track | Sino Biopharm Shares Soar on Subsidiary's Share Buyback
Stock Track  ·  10-04
Stock Track | Sino Biopharm Shares Soar on Subsidiary's Share Buyback
Sino Biopharmaceutical Unit Buys 187 Milion Shares Under Award Scheme
MT Newswires Live  ·  10-04
Sino Biopharmaceutical Unit Buys 187 Milion Shares Under Award Scheme
After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar
Simply Wall St.  ·  10-03
After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar
Chinese Regulator Approves Sino Biopharmaceutical's Alzheimer Treatment Patch for Marketing
MT Newswires Live  ·  09-25
Chinese Regulator Approves Sino Biopharmaceutical's Alzheimer Treatment Patch for Marketing
Sino Biopharmaceutical - Approval for Marketing of "Rivastigmine Transdermal Patch" by Nmpa
THOMSON REUTERS  ·  09-25
Sino Biopharmaceutical - Approval for Marketing of "Rivastigmine Transdermal Patch" by Nmpa

Introduction

Company Name.
SINO BIOPHARM
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Sino Biopharmaceutical Limited is an investment holding company principally engaged in the medicine products business. The Company operates through three business segments. The Modernized Chinese Medicines and Chemical Medicines segment is engaged in the manufacture, sales and distribution of modernized Chinese medicine products and western medicine products. The Investment segment is engaged in long term investments. The Others segment is engaged in the provision of research and development activities and services to third parties, as well as related healthcare and hospital business. The Company is also involved in the property holding, the sales of health food, the manufacture and optometry of optical glasses, as well as the retail and wholesale of optical and auditory products through its subsidiaries.
Issue price:
--